<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02633553</url>
  </required_header>
  <id_info>
    <org_study_id>1508151-4</org_study_id>
    <nct_id>NCT02633553</nct_id>
  </id_info>
  <brief_title>Adjuvant Radiotherapy for Stage II/III Thymoma After Complete Resection</brief_title>
  <official_title>An Open-label, Multi-center, Randomized Phase III Study of Adjuvant Radiotherapy for Stage II/III Thymoma After Complete Resection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to investigate whether adjuvant radiotherapy after complete resection
      has a better survival for stage II or III thymoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is confirmed by many studies that patients of thymoma with complete resection have better
      prognosis than those with either incomplete resection or without surgery. However,whether
      patients with stage II or III thymoma could benefit from adjuvant radiotherapy after complete
      resection remains controversial. The purpose of this study is to investigate whether adjuvant
      radiotherapy after complete resection can improve survival for stage II or III thymoma.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DFS (Disease free survival)</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS(overall survival)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1</enrollment>
  <condition>Thymoma</condition>
  <arm_group>
    <arm_group_label>radiotherapy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>complete resection and adjuvant radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>observation group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>complete resection</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>adjuvant radiotherapy</intervention_name>
    <description>50Gy/25Fx</description>
    <arm_group_label>radiotherapy group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        18~75 years old; Eastern Cooperative Oncology Group performance status of 0 to 2;
        Pathologically confirmed masaoka stage II or III thymoma; Have adequate bone marrow,
        hepatic, and renal function; Patients receive complete resection within 3 months; Written
        informed consent.

        Exclusion Criteria:

        Patients with distant metastases; Patients underwent radiotherapy or chemotherapy; Patients
        who have malignancy history excluding carcinoma in situ of cervix in the previous five
        years; Active clinical pulmonary infection; Pregnant or nursing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kailiang Wu, MD.PhD.</last_name>
    <phone>+86 64175590</phone>
    <phone_ext>86722</phone_ext>
    <email>wukailiang@aliyun.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yu Yang</last_name>
    <email>niujiu99@sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kailiang Wu</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>20032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kailiang Wu, M.D. Ph. D.</last_name>
      <phone>+86 64175590</phone>
      <phone_ext>86722</phone_ext>
      <email>wukailiang@aliyun.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2015</study_first_submitted>
  <study_first_submitted_qc>December 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2015</study_first_posted>
  <last_update_submitted>August 11, 2016</last_update_submitted>
  <last_update_submitted_qc>August 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Kailiang Wu</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>thymoma</keyword>
  <keyword>adjuvant radiotherapy</keyword>
  <keyword>complete resection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thymoma</mesh_term>
    <mesh_term>Thymus Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

